Conjugate pneumococcal vaccines for non-indigenous children in Australia.
Childhood pneumococcal disease is associated with substantial morbidity and mortality, but total disease burden is more difficult to measure than for invasive disease caused by Haemophilus influenzae type b (Hib). A safe, effective seven-valent conjugate pneumococcal vaccine will be available in Australia by early 2001, and will certainly be indicated for high-risk groups and purchased in the private sector, as was Hib vaccine. The status of this vaccine on the Australian Standard Vaccination Schedule will require more detailed consideration of the burden and serotype distribution of pneumococcal disease in Australian children and the vaccine's likely cost-effectiveness. Postmarketing surveillance will be particularly important.
McIntyre
P B
PB
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, New Children's Hospital, Sydney, NSW. peterm@nch.edu.au
Nolan
T M
TM
D001315:Australia / Q000453:epidemiology; D002648:Child; D019741:Haemophilus influenzae type b / Q000145:classification; D006801:Humans; D015994:Incidence; D007223:Infant; D008004:Licensure; D010033:Otitis Media / Q000453:epidemiology / Q000517:prevention & control; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000145:classification; D016032:Randomized Controlled Trials as Topic; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification*
D022242:Pneumococcal Vaccines